Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-γ for metastatic renal cell carcinoma

Nizar Tannir, Eric Jonasch, Lance C. Pagliaro, Paul Mathew, Arlene Siefker-Radtke, Laurence Rhines, Patrick Lin, Rita Tibbs, Kim Anh Do, Sue Hwa Lin, Shi Ming Tu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

BACKGROUND. The purpose of the study was to evaluate the efficacy and safety of a bone-targeted regimen consisting of zoledronate, thalidomide, and interferon-γ in patients with renal cell carcinoma and bone metastases. METHODS. Eligible patients had radiographic evidence of bone metastasis. Impending pathologic fractures or spinal cord compressions must have been controlled by surgery or radiation therapy before enrollment. Zoledronate (4 mg) was given intravenously every 4 weeks, thalidomide (300 mg) was given orally once a day, and interferon-γ (100 μg) was given subcutaneously once a week. Patients were evaluated for time to skeletal-related events, the appearance of calcification in osteolytic metastases, and levels of the bone formation/resorption markers. RESULTS. Fifteen patients were treated between November 2002 and November 2003; 12 had previously undergone surgery, radiation, or embolization for their bone metastases; 11 had more than 3 sites of bone involvement; and 9 also had nonosseous metastases in the lung, liver, lymph node, pancreas, or adrenal gland. The median time to progression was 8.3 weeks (range, 2.1-48 weeks). The median time to a skeletal-related event was 12.0 weeks (range, 3.9-46.4 weeks). Two patients discontinued treatment because of adverse drug reactions (1 deep venous thrombosis and 1 myocardial infarction). Two patients experienced pain improvement and developed calcification in osseous metastases; these patients also showed favorable changes in bone marker levels. CONCLUSIONS. In this pilot study a bone-targeted regimen combining zoledronate, thalidomide, and interferon-γ was well tolerated and might provide clinical benefit for a small subset of patients with renal cell carcinoma and bone metastases.

Original languageEnglish (US)
Pages (from-to)497-505
Number of pages9
JournalCancer
Volume107
Issue number3
DOIs
StatePublished - Aug 1 2006
Externally publishedYes

Fingerprint

zoledronic acid
Thalidomide
Renal Cell Carcinoma
Interferons
Bone and Bones
Neoplasm Metastasis
Therapeutics
Spontaneous Fractures
Spinal Cord Compression
Bone Resorption
Adrenal Glands
Drug-Related Side Effects and Adverse Reactions
Osteogenesis
Venous Thrombosis

Keywords

  • Bisphosphonates
  • Bone metastasis
  • Renal cell carcinoma
  • Zoledronate

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Tannir, N., Jonasch, E., Pagliaro, L. C., Mathew, P., Siefker-Radtke, A., Rhines, L., ... Tu, S. M. (2006). Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-γ for metastatic renal cell carcinoma. Cancer, 107(3), 497-505. https://doi.org/10.1002/cncr.22038

Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-γ for metastatic renal cell carcinoma. / Tannir, Nizar; Jonasch, Eric; Pagliaro, Lance C.; Mathew, Paul; Siefker-Radtke, Arlene; Rhines, Laurence; Lin, Patrick; Tibbs, Rita; Do, Kim Anh; Lin, Sue Hwa; Tu, Shi Ming.

In: Cancer, Vol. 107, No. 3, 01.08.2006, p. 497-505.

Research output: Contribution to journalArticle

Tannir, N, Jonasch, E, Pagliaro, LC, Mathew, P, Siefker-Radtke, A, Rhines, L, Lin, P, Tibbs, R, Do, KA, Lin, SH & Tu, SM 2006, 'Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-γ for metastatic renal cell carcinoma', Cancer, vol. 107, no. 3, pp. 497-505. https://doi.org/10.1002/cncr.22038
Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L et al. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-γ for metastatic renal cell carcinoma. Cancer. 2006 Aug 1;107(3):497-505. https://doi.org/10.1002/cncr.22038
Tannir, Nizar ; Jonasch, Eric ; Pagliaro, Lance C. ; Mathew, Paul ; Siefker-Radtke, Arlene ; Rhines, Laurence ; Lin, Patrick ; Tibbs, Rita ; Do, Kim Anh ; Lin, Sue Hwa ; Tu, Shi Ming. / Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-γ for metastatic renal cell carcinoma. In: Cancer. 2006 ; Vol. 107, No. 3. pp. 497-505.
@article{c1f7e185d9cf4580b3c326ae36ab899f,
title = "Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-γ for metastatic renal cell carcinoma",
abstract = "BACKGROUND. The purpose of the study was to evaluate the efficacy and safety of a bone-targeted regimen consisting of zoledronate, thalidomide, and interferon-γ in patients with renal cell carcinoma and bone metastases. METHODS. Eligible patients had radiographic evidence of bone metastasis. Impending pathologic fractures or spinal cord compressions must have been controlled by surgery or radiation therapy before enrollment. Zoledronate (4 mg) was given intravenously every 4 weeks, thalidomide (300 mg) was given orally once a day, and interferon-γ (100 μg) was given subcutaneously once a week. Patients were evaluated for time to skeletal-related events, the appearance of calcification in osteolytic metastases, and levels of the bone formation/resorption markers. RESULTS. Fifteen patients were treated between November 2002 and November 2003; 12 had previously undergone surgery, radiation, or embolization for their bone metastases; 11 had more than 3 sites of bone involvement; and 9 also had nonosseous metastases in the lung, liver, lymph node, pancreas, or adrenal gland. The median time to progression was 8.3 weeks (range, 2.1-48 weeks). The median time to a skeletal-related event was 12.0 weeks (range, 3.9-46.4 weeks). Two patients discontinued treatment because of adverse drug reactions (1 deep venous thrombosis and 1 myocardial infarction). Two patients experienced pain improvement and developed calcification in osseous metastases; these patients also showed favorable changes in bone marker levels. CONCLUSIONS. In this pilot study a bone-targeted regimen combining zoledronate, thalidomide, and interferon-γ was well tolerated and might provide clinical benefit for a small subset of patients with renal cell carcinoma and bone metastases.",
keywords = "Bisphosphonates, Bone metastasis, Renal cell carcinoma, Zoledronate",
author = "Nizar Tannir and Eric Jonasch and Pagliaro, {Lance C.} and Paul Mathew and Arlene Siefker-Radtke and Laurence Rhines and Patrick Lin and Rita Tibbs and Do, {Kim Anh} and Lin, {Sue Hwa} and Tu, {Shi Ming}",
year = "2006",
month = "8",
day = "1",
doi = "10.1002/cncr.22038",
language = "English (US)",
volume = "107",
pages = "497--505",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-γ for metastatic renal cell carcinoma

AU - Tannir, Nizar

AU - Jonasch, Eric

AU - Pagliaro, Lance C.

AU - Mathew, Paul

AU - Siefker-Radtke, Arlene

AU - Rhines, Laurence

AU - Lin, Patrick

AU - Tibbs, Rita

AU - Do, Kim Anh

AU - Lin, Sue Hwa

AU - Tu, Shi Ming

PY - 2006/8/1

Y1 - 2006/8/1

N2 - BACKGROUND. The purpose of the study was to evaluate the efficacy and safety of a bone-targeted regimen consisting of zoledronate, thalidomide, and interferon-γ in patients with renal cell carcinoma and bone metastases. METHODS. Eligible patients had radiographic evidence of bone metastasis. Impending pathologic fractures or spinal cord compressions must have been controlled by surgery or radiation therapy before enrollment. Zoledronate (4 mg) was given intravenously every 4 weeks, thalidomide (300 mg) was given orally once a day, and interferon-γ (100 μg) was given subcutaneously once a week. Patients were evaluated for time to skeletal-related events, the appearance of calcification in osteolytic metastases, and levels of the bone formation/resorption markers. RESULTS. Fifteen patients were treated between November 2002 and November 2003; 12 had previously undergone surgery, radiation, or embolization for their bone metastases; 11 had more than 3 sites of bone involvement; and 9 also had nonosseous metastases in the lung, liver, lymph node, pancreas, or adrenal gland. The median time to progression was 8.3 weeks (range, 2.1-48 weeks). The median time to a skeletal-related event was 12.0 weeks (range, 3.9-46.4 weeks). Two patients discontinued treatment because of adverse drug reactions (1 deep venous thrombosis and 1 myocardial infarction). Two patients experienced pain improvement and developed calcification in osseous metastases; these patients also showed favorable changes in bone marker levels. CONCLUSIONS. In this pilot study a bone-targeted regimen combining zoledronate, thalidomide, and interferon-γ was well tolerated and might provide clinical benefit for a small subset of patients with renal cell carcinoma and bone metastases.

AB - BACKGROUND. The purpose of the study was to evaluate the efficacy and safety of a bone-targeted regimen consisting of zoledronate, thalidomide, and interferon-γ in patients with renal cell carcinoma and bone metastases. METHODS. Eligible patients had radiographic evidence of bone metastasis. Impending pathologic fractures or spinal cord compressions must have been controlled by surgery or radiation therapy before enrollment. Zoledronate (4 mg) was given intravenously every 4 weeks, thalidomide (300 mg) was given orally once a day, and interferon-γ (100 μg) was given subcutaneously once a week. Patients were evaluated for time to skeletal-related events, the appearance of calcification in osteolytic metastases, and levels of the bone formation/resorption markers. RESULTS. Fifteen patients were treated between November 2002 and November 2003; 12 had previously undergone surgery, radiation, or embolization for their bone metastases; 11 had more than 3 sites of bone involvement; and 9 also had nonosseous metastases in the lung, liver, lymph node, pancreas, or adrenal gland. The median time to progression was 8.3 weeks (range, 2.1-48 weeks). The median time to a skeletal-related event was 12.0 weeks (range, 3.9-46.4 weeks). Two patients discontinued treatment because of adverse drug reactions (1 deep venous thrombosis and 1 myocardial infarction). Two patients experienced pain improvement and developed calcification in osseous metastases; these patients also showed favorable changes in bone marker levels. CONCLUSIONS. In this pilot study a bone-targeted regimen combining zoledronate, thalidomide, and interferon-γ was well tolerated and might provide clinical benefit for a small subset of patients with renal cell carcinoma and bone metastases.

KW - Bisphosphonates

KW - Bone metastasis

KW - Renal cell carcinoma

KW - Zoledronate

UR - http://www.scopus.com/inward/record.url?scp=33746277238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746277238&partnerID=8YFLogxK

U2 - 10.1002/cncr.22038

DO - 10.1002/cncr.22038

M3 - Article

C2 - 16795067

AN - SCOPUS:33746277238

VL - 107

SP - 497

EP - 505

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -